Aradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin, which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company's formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).